两分次超低分次放疗联合局灶推量治疗中危局限性前列腺癌(TURBO):一项II期随机对照临床试验的研究方案
TURBO为单中心、开放标签、随机对照II期试验,计划纳入160例中危局限性前列腺癌患者,1:1随机接受标准5分次放疗(36.25 Gy/5次,16–18天完成)或试验组2分次放疗(前列腺12 Gy/次,GTV同期整合推量至13.5 Gy,8天完成),主要终点为CTCAE≥2级急性泌尿生殖毒性(治疗后90天内),旨在评估试验方案的非劣效性。
要点
- 试验组为前列腺2分次12 Gy/次,GTV同期整合推量至13.5 Gy,8天完成。
- 对照组为标准5分次7.25 Gy/次,总36.25 Gy,16–18天完成。
- 主要终点为CTCAE≥2级急性泌尿生殖毒性(治疗后90天内)。
核心结论
- TURBO试验旨在评估2分次超低分次放疗联合GTV局灶推量在中危局限性前列腺癌中的安全性与耐受性,并比较肿瘤学结局。
研究设计与样本
- 单中心、开放标签、随机对照II期试验,设计为非劣效性检验,数据收集于MOMENTUM纵向研究。
- 计划纳入160例中危局限性前列腺癌患者,在1.5 T MR-Linac上治疗,按1:1随机分组。
- 对照组80例接受标准治疗:36.25 Gy分5次,16–18天完成。
- 试验组80例接受2分次放疗:前列腺12 Gy/次,GTV推量至13.5 Gy,8天完成。
主要发现
- 主要终点为CTCAE≥2级急性泌尿生殖毒性(治疗后90天内)。
- 次要结局包括急性胃肠道毒性及治疗后1、2、5年的晚期泌尿生殖和胃肠道毒性。
- 次要结局还包括通过EORTC-QLQ-C30、EORTC-QLQ-PR15、EQ-5D-5L评估的生活质量,以及至5年的生化复发和总生存。
关键数值与推荐
- 试验组:前列腺12 Gy/次×2次,GTV同期整合推量至13.5 Gy,8天完成。
- 对照组:7.25 Gy/次×5次,总36.25 Gy,16–18天完成。
- 主要终点:CTCAE≥2级急性泌尿生殖毒性,评估至治疗后90天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypofractionation in prostate cancer radiotherapy (RT) has drastically reduced fractionation schemes from 35 to 5 fractions for patients with intermediate-risk prostate cancer, providing good oncological outcomes and well-tolerated treatment toxicity. With an ageing population and a subsequently higher volume of patients with localized prostate cancer, optimizing treatment options is essential to maintain a sustainable healthcare system. Magnetic resonance (MR)-guided RT, allows for the delivery of higher doses of radiation with more accuracy, while limiting genitourinary (GU) and gastrointestinal (GI) toxicity. These advantages facilitate the development of ultrahypofractionation schedules in which the number of treatment fractions can be decreased whilst delivering a sufficient dose for oncological control. The objective of the Two-fraction Ultrahypofractionated Radiotherapy with focal BOost (TURBO) trial is to assess if a radiotherapy schedule of 24 Gy to the prostate in two fractions with a boost to the intraprostatic tumor of up to 27 Gy, is safe and tolerable in terms of treatment toxicity, quality of life, and oncological outcomes. METHODS: TURBO is a single-center, open-label, randomized controlled trial, designed to assess non-inferiority over standard treatment. Data are collected within the longitudinal Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM). We will include 160 patients with intermediate risk, localized prostate cancer, who are treated on a 1.5 T MR-linear accelerator (MR-Linac) and randomized (1:1). Participants in the control arm (n = 80) will receive standard of care (36.25 Gy in five fractions, delivered in 16-18 days). Participants in the experimental arm (n = 80) are treated with two fractions of 12 Gy to the prostate, with a boost of up to 13.5 Gy to the gross tumor volume (GTV) in 8 days. The main endpoint is Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 2 GU acute toxicity (up to 90 days after treatment). Secondary outcomes are acute GI toxicity and late GU and GI toxicity 1, 2, and 5 years after treatment, as well as QoL through assessment of patient-reported outcome measures (EORTC-QLQ-C30, EORTC-QLQ-PR15, EQ-5D-5L) and biochemical recurrence and overall survival up to 5 years. DISCUSSION: TURBO compares a 2-fraction radiotherapy course of 12 Gy per fraction to the clinical target volume (CTV) with a simultaneously integrated boost to the GTV of up to 13.5 Gy to a standard 5-fraction course of 7.25 Gy per fraction. The objective is to assess non-inferiority in terms of treatment toxicity and to compare oncological outcomes. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT06518226. Registered on 24 July 2024. First participant included on March 28th 2024.
引用
- Lalmahomed TA, Monninkhof EM, van Rijssel MJ, et al. Two-fraction Ultrahypofractionated Radiotherapy with focal BOost for intermediate-risk, localized prostate cancer (TURBO): study protocol of a phase II, randomized controlled clinical trial. Trials. 2025. PMID: 41466435. doi:10.1186/s13063-025-09297-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。